Publication:
abstract
OBJECTIVE:
cerebral vasospasm is the commonest cause for mortality and morbidity in patients following clipping of a ruptured aneurysm. Selective phosphodiesterase (PDE) inhibitor like sildenafil acts as a vasodilator. The objective of this study was to evaluate the Safety and feasibility of oral sildenafil citrate in patients with symptomatic refractory vasospasm.
METHODS:
A total of 832 patients with aneurysmal subarachnoid bleed were operated in 4 years. Two hundred and seventy-three patients had vasospasm. Of these, 72 patients had refractory cerebral vasospasm. Vasospasm was defined as refractory when institution of "HHH" failed to reverse the transcranial Doppler (TCD) values even after 24 hours. Computed tomography (CT) scan showed no infarct, hematoma, or hydrocephalus, and the serum electrolytes were within normal limits. They received 100-150 mg of sildenafil every 4 hours. Response was evaluated by 2-hourly TCD.
RESULTS:
Eight patients had sustained (TCD values normal for >48 hours) and four had temporary relief in vasospasm, as suggested. Four patients developed complications significant enough to terminate the therapy.
CONCLUSIONS:
Sildenafil citrate may be effective in patients with refractory symptomatic vasospasm. It calls upon the pharmacologists and scientists to discover newer supraselective PDE inhibitors, specific to PDE receptors in brain vessels.
Related Articles
Reversal of severe cerebral vasospasm in three patients after aneurysmal subarachnoid hemorrhage: initial observations regarding the use of intraventricular sodium nitroprusside in humans.
Neurosurgery. 1999
Reversal of severe cerebral vasospasm in three patients after aneurysmal subarachnoid hemorrhage: initial observations regarding the use of intraventricular sodium nitroprusside in humans.
Thomas JE, Rosenwasser RH. Neurosurgery. 1999 Jan; 44(1):48-57; discussion 57-8.
Intraventricular sodium nitroprusside therapy: a future promise for refractory subarachnoid hemorrhage-induced vasospasm.
Neurol India. 2003
Intraventricular sodium nitroprusside therapy: a future promise for refractory subarachnoid hemorrhage-induced vasospasm.
Kumar R, Pathak A, Mathuriya SN, Khandelwal N. Neurol India. 2003 Jun; 51(2):197-202.
Systemic administration of phosphodiesterase V inhibitor, sildenafil citrate, for attenuation of cerebral vasospasm after experimental subarachnoid hemorrhage.
Neurosurgery. 2006
Systemic administration of phosphodiesterase V inhibitor, sildenafil citrate, for attenuation of cerebral vasospasm after experimental subarachnoid hemorrhage.
Atalay B, Caner H, Cekinmez M, Ozen O, Celasun B, Altinors N. Neurosurgery. 2006 Nov; 59(5):1102-7; discussion 1107-8.
Review Role of intraventricular sodium nitroprusside in vasospasm secondary to aneurysmal subarachnoid haemorrhage: a 5-year prospective study with review of the literature.
Minim Invasive Neurosurg. 2009
Review Role of intraventricular sodium nitroprusside in vasospasm secondary to aneurysmal subarachnoid haemorrhage: a 5-year prospective study with review of the literature.
Agrawal A, Patir R, Kato Y, Chopra S, Sano H, Kanno T. Minim Invasive Neurosurg. 2009 Feb; 52(1):5-8. Epub 2009 Feb 26.
Review The efficacy and safety of angioplasty for cerebral vasospasm after subarachnoid hemorrhage.
Neurosurgery. 1998
Review The efficacy and safety of angioplasty for cerebral vasospasm after subarachnoid hemorrhage.
Bejjani GK, Bank WO, Olan WJ, Sekhar LN. Neurosurgery. 1998 May; 42(5):979-86; discussion 986-7.